Corvus Pharmaceuticals Inc. Common Stock (CRVS)

FairStock Score: 19/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Corvus as a Graham-style analyst: it is a clinical-stage biotech with no reported revenue and no profits. At the close on 2026-10-13, the price was $9.41 and the market capitalization was $791.6 million. FairStock’s calculations show a negative P/E of -14.70, a P/B of 3.51, ROE of -35.43%, ROCE of -21.66%, and trailing free cash flow of -$45.2 million, or a -5.7% FCF yield. Those are not marks of a proven business; they are marks of a research enterprise funded by investors. The filed numbers confirm the pattern: net losses of $27.0 million in fiscal year 2023, $62.3 million in fiscal year 2024, and $15.3 million in fiscal year 2025, followed by $13.7 million in fiscal Q1 2026, the quarter ended 2026-03-31, and $18.0 million in fiscal Q2 2026, the quarter ended 2026-06-30. The loss in fiscal Q2 2026 was wider than the $8.0 million loss in fiscal Q2 2025, the quarter ended 2025-06-30, so the recent trend is not self-funding maturity. The balance sheet has no debt according to the D/E of 0.00, and the FairStock Altman Z-Score is 32.50, but the Piotroski F-Score is only 1/9 and the FairStock Score is 19/100. The Lynch category is none because Corvus has lost money in each of the last four years. I cannot identify a durable moat: value depends on soquelitinib and clinical outcomes in peripheral T cell lymphoma and atopic dermatitis. I would call this speculative, not an investment in a proven earnings stream.

In plain English: Corvus Pharmaceuticals is a small drug development company with 37 employees. It has no product sales yet and has lost money every recent year, with cash going out faster than it comes in. At the 2026-10-13 close of $9.41, the price looks expensive compared with its current financial results because there are no profits or revenue to support it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer